Hepatitis C Virus Structure: Defined by What It Is Not
Overview
Affiliations
Hepatitis C virus (HCV) represents an important and growing public health problem, chronically infecting an estimated 70 million people worldwide. This blood-borne pathogen is generating a new wave of infections in the United States, associated with increasing intravenous drug use over the last decade. In most cases, HCV establishes a chronic infection, sometimes causing cirrhosis, end-stage liver disease, and hepatocellular carcinoma. Although a curative therapy exists, it is extremely expensive and provides no barrier to reinfection; therefore, a vaccine is urgently needed. The virion is asymmetric and heterogeneous with the buoyancy and protein content similar to low-density lipoparticles. Core protein is unstructured, and of the two envelope glycoproteins, E1 and E2, the function of E1 remains enigmatic. E2 is responsible for specifically binding host receptors CD81 and scavenger receptor class B type I (SR-BI). This review will focus on structural progress on HCV virion, core protein, envelope glycoproteins, and specific host receptors.
Yuan H, Xu R, Li S, Zheng M, Tong Q, Xiang M MedComm (2020). 2025; 6(3):e70121.
PMID: 40060195 PMC: 11890166. DOI: 10.1002/mco2.70121.
Costa G, Sautto G Vaccines (Basel). 2024; 12(8).
PMID: 39204016 PMC: 11359689. DOI: 10.3390/vaccines12080890.
Understanding the relationship between HCV infection and progression of kidney disease.
Zhang M, Han Z, Lin Y, Jin Z, Zhou S, Wang S Front Microbiol. 2024; 15:1418301.
PMID: 39006752 PMC: 11239345. DOI: 10.3389/fmicb.2024.1418301.
Antiviral Protein-Protein Interaction Inhibitors.
Markovic V, Szczepanska A, Berlicki L J Med Chem. 2024; 67(5):3205-3231.
PMID: 38394369 PMC: 10945500. DOI: 10.1021/acs.jmedchem.3c01543.
Structure of engineered hepatitis C virus E1E2 ectodomain in complex with neutralizing antibodies.
Metcalf M, Janus B, Yin R, Wang R, Guest J, Pozharski E Nat Commun. 2023; 14(1):3980.
PMID: 37407593 PMC: 10322937. DOI: 10.1038/s41467-023-39659-z.